Canagliflozin,
does it really help with Delayed aging and extended healthspan and total lifespan in healthy people without diabetes?
research showsCanagliflozin receives a question-mark grade because no human efficacy literature shows delayed aging or longer healthspan or total lifespan in healthy people without diabetes. In the NIA Interventions Testing Program, treatment from seven months of age increased median lifespan by 14% and 90th-percentile lifespan by 9% in genetically heterogeneous male mice, but did not extend female lifespan. Cardiac and kidney benefits of SGLT inhibitors concern disease outcomes in diabetes, heart failure, or chronic kidney disease and cannot be transferred to healthy-human aging and lifespan. This axis is distinct from disease-specific SGLT2 verdicts such as dapagliflozin in verdict 1002.
ads claimMarketing may turn a 14% male-mouse lifespan increase or cardiac and kidney protection in patients into an anti-aging drug for healthy people. Animal longevity and disease-specific clinical effects do not establish longer survival in healthy humans or erase prescription-drug harms.
Useful facts when choosing a product
- Canagliflozin is a prescription drug for type 2 diabetes and selected cardiac and kidney risk reduction; it is not approved to slow aging or extend lifespan in healthy people.
- Increased urinary glucose can cause genital fungal infection, frequent urination, volume depletion, and hypotension, particularly in older adults or people taking diuretics.
- Ketoacidosis can occur even with normal or only mildly elevated glucose, so fasting, acute illness, and the perioperative period require expert guidance.
- A lower-limb amputation signal has been reported, so foot ulcers and peripheral vascular risk require assessment; no net benefit is established for longevity self-treatment by healthy people.
What the research actually shows
The NIA ITP study by Miller and colleagues fed UM-HET3 mice canagliflozin at 180 ppm from seven months of age. Median lifespan increased by 14% and 90th-percentile lifespan by 9% in males, but female lifespan did not increase. Follow-up mechanistic and pathology work explored selected age-related lesions and mTOR and MAPK signaling, not human longevity. A 2023 review of SGLT inhibitors and healthspan proposed clinical potential from cardiac, kidney, and observational evidence but concluded that further randomized trials must test healthspan and lifespan directly.
Why this is classified as ?
Male-mouse ITP longevity and cardiac and kidney effects in disease populations do not substitute for a completed intervention measuring aging rate, healthspan, or total lifespan in healthy people without diabetes. The human-efficacy-literature absence rule gives a question mark and a null score.
Counterpoint. Strong preclinical evidence can justify human research, but it does not support anti-aging prescribing until long-term randomized studies jointly assess efficacy and harms such as ketoacidosis, infection, and volume depletion in healthy people.
Rejudgment record. Cross-check applied — Treated the NIA ITP 14% median-lifespan increase in male mice as a preclinical hypothesis only and applied the unknown grade because no completed human intervention efficacy result addresses delayed aging, healthspan, or total lifespan in healthy people without diabetes; SGLT2 benefits in diabetes and cardiac or kidney disease were not transferred
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Delayed aging in healthy people without diabetes with canagliflozin | ? | No completed human intervention efficacy result directly evaluates aging rate. |
| Extended healthspan in healthy people without diabetes with canagliflozin | ? | No human intervention result uses healthspan itself as an outcome. |
| Extended total lifespan in healthy people without diabetes with canagliflozin | ? | Only male-mouse evidence exists, with no total-lifespan result in healthy humans. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Miller RA et al. 2020 NIA ITP | Three-site lifespan intervention study in genetically heterogeneous mice | 180 | United States National Institute on Aging Interventions Testing Program | Median lifespan, 90th-percentile lifespan, and end-of-life pathology | Male median lifespan increased 14% and 90th-percentile lifespan 9%; female lifespan did not increase. | Strong preclinical longevity hypothesis without direct human evidence |
| O’Keefe JH et al. 2023 | Narrative evidence review of SGLT inhibitors for healthspan and lifespan | Academic review with author disclosures | Age-related disease, mortality, and healthspan and lifespan hypotheses | The review proposed potential but concluded that further randomized trials must directly test healthspan and lifespan. | Confirmation of the human efficacy gap |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Canagliflozin x delayed aging and extended healthspan and lifespan in healthy people without diabetes — Evidence Grade ?. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/canagliflozin-healthy-nondiabetic-aging-healthspan-lifespan/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.